Skip to content
Home / News |

Relief Therapeutics Share Price Up 2,100%, COVID Drug Ready in “Few Months”

Stock market or forex trading graph in graphic concept
Nigel F

Shares of Relief Therapeutics’ (SIX: RLF) closed the week 1,341% higher after its RLF-100 COVID-19 treatment showed an early potential in the second testing phase.

The chairman of the firm, Raghuram Selvaraju, believes that there is a “60%-70%” chance to get approval for the drug. 

“From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70% that we will get the drug approved,” Selvaraju told Swiss newspaper The Market.

X testing X
WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
5.0
Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

“The active pharmaceutical ingredient of aviptadil has been used for a lot of years in different indications. From a safety standpoint we are quite optimistic,” he added.

Relief holds a patent for Europe and the United States. It partnered with NeuroRx to run multicentre clinical trials. RLF-100 is targeting patients who are severely ill with COVID-19 infections, helping them to survive.

“I do not anticipate that we would need ten to 12 months for approval,” he concluded.

Relief Therapeutics’ share price gained on COVID-19 treatment August 2020

Relief Therapeutics’ share price closed 1,341% higher after trading over 2,100% in the green on Thursday. 

Nigel F
Nigel F
Team Member

Nigels tiefes Verständnis der Finanzmärkte basiert auf über 10 Jahren Erfahrung. Nigel wurde bisher zweimal von der FCA (Financial Conduct Authority) autorisiert und hat in der letzten Zeit eine Finanz-Brokerage Firma besessen und verkauft. Er liefert hochaktuelle Analysen und Einsichten in die Finanzmärkte und in die allgemeine Wirtschafts- und Währungspolitik des Vereinigten Königreichs, der USA, Europas und Asiens.